logo

For the Inventor, By the Inventor

Glendale, WI, United States of America

Michael W Major

This inventor holds 7 USPTO granted patents and 1 EPO patent. Top assignees: Avanir Pharmaceuticals, Amicus Therapeutics, Inc., Other. Active years: 2001-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael W Major. Retrieved from https://idiyas.com/inventor/michael-w-major-djbrchdp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 42.9


Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 130(Granted Patents)


Location History:

  • Glendale, WI (US) (2001 - 2002)
  • Mequon, WI (US) (2005 - 2011)

Company Filing History:

goldMedal5 out of 38 
 
Avanir Pharmaceuticals
 patents
silverMedal1 out of 161 
 
Amicus Therapeutics, Inc.
 patents
bronzeMedal1 out of 834,513 
Other
 patents

Years Active: 2001-2011

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 7973157 - Imino and amino sugar purification (2011-07-05),
2. 6919366 - Benzimidazole derivatives as modulators of IgE (2005-07-19),
3. 6911462 - Benzimidazole compounds for regulating IgE (2005-06-28),
4. 6451829 - Coumarinic compounds having IgE affecting properties (2002-09-17),
5. 6369091 - Benzimidazole analogs as down-regulators of IgE (2002-04-09),
6. 6303645 - Benzimidazole derivatives as modulators of IgE (2001-10-16),
7. 6271390 - Suppression of the IgE-dependent allergic response by benzimidazole analogs (2001-08-07),

Title: The Innovative Contributions of Michael W. Major

Introduction

Michael W. Major is a notable inventor based in Glendale, Wisconsin, who has made significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, Major has focused on developing novel processes and compounds that address critical health issues.

Latest Patents

Among his latest patents, Major has developed processes for the purification of imino and amino sugars, specifically D-1-deoxygalactonojirimycin (DGJ). These innovative methods utilize hydrochloric acid for the purification of multi-kilogram scale sugars. Additionally, he has created a family of benzimidazole derivatives that serve as modulators of IgE, which are crucial in treating allergies, asthma, and other diseases where IgE is pathogenic.

Career Highlights

Throughout his career, Major has worked with prominent companies in the pharmaceutical industry, including Avanir Pharmaceuticals and Amicus Therapeutics, Inc. His work has been instrumental in advancing therapeutic options for patients suffering from various conditions.

Collaborations

Major has collaborated with esteemed colleagues such as Jagadish C. Sircar and Mark L. Richards, contributing to the development of innovative solutions in his field.

Conclusion

Michael W. Major's contributions to pharmaceutical innovations through his patents and collaborations highlight his commitment to improving health outcomes. His work continues to influence the industry and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…